Provectus starts compassionate use program for PV-10

Provectus starts compassionate use program for PV-10

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009. The program for PV-10 is being implemented under the FDA’s guidelines covering compassionate use of an investigational new drug.

Read the release.